H2AX and breast cancer: Our findings in a study with 48 BC cases (with blood drawn prior to BC diagnosis) and 48 matched controls suggest that residual γ-H2AX damage (designated here as Fres), measured in PBMC B cells at 20 hrs after DNA damage challenge, is systematically lower in women who were subsequently diagnosed with breast cancer, relative to the matched controls.